Study Comparing Dextran 40 Plus Ringers Lactate Combination to Ringers Lactate Alone for Treating Mild and Moderate Acute Pancreatitis

What this Trial Is About

Researchers are evaluating whether a combination of Dextran 40 and Ringers lactate solution improves fluid resuscitation in adults with mild and moderate acute pancreatitis compared to Ringers lactate alone. The study aims to find out if this combined treatment reduces inflammation, organ failure, and the need for intensive care. This randomized controlled trial involves about 100 patients at a hospital setting to better understand the best approach for fluid management in acute pancreatitis. Participants will receive either a mix of Dextran 40 and Ringers lactate in a 13 ratio or only Ringers lactate, administered at a rate of 1.5 mL per kilogram per hour, adjusted to each patients condition. The study interventions are given early after hospital admission. The trial compares the two treatments to see which better prevents disease progression and complications. During the study, patients will have blood tests every 24 hours to monitor pancreatic enzymes, inflammation markers like C-reactive protein, and organ function. Ultrasound will assess central venous pressure, and urine output will be tracked as a sign of adequate resuscitation. The main outcomes measured include reduction of systemic inflammatory response syndrome SIRS and C-reactive protein levels from admission to day 4 or discharge. Patients will be observed during their hospital stay and followed up 12 weeks after discharge to assess longer-term effects.

Dextran 40 Plus Ringer's Lactate Vs. Ringer's Lactate Alone for Fluid Resuscitation in Acute Pancreatitis